HopeStage
Back to all studies
Enrolling By InvitationNCT06878976

Safety study of Long-term Safety and Efficacy of Solriamfetol in Binge-Eating disorders

Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.

Medication studyAges 18–56United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.

Who could participate?

Listed age limits: 18 years to 56 years.

Listed locations
Encino and 32 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 20, 2025
Recruitment status
Enrolling By Invitation
Enrollment listed in the registry
236
Sponsor
Axsome Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 56 Years
Official registry ID
NCT06878976
Official title
Show the full official title

An Open-Label and Double-Blind, Randomized Withdrawal Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder

Recruitment & locations

By invitation

Encino · Long Beach · Santa Ana

29 more locations
  • Walnut Creek
  • West Covina
  • Colorado Springs
  • Cromwell
  • Fort Myers
  • Jacksonville
  • Lauderhill
  • Miami
  • Miami Lakes
  • Orlando
  • Marietta
  • Overland Park
  • Boston
  • Saint Charles
  • Cherry Hill
  • Mount Kisco
  • New York
  • Raleigh
  • Cincinnati
  • Mason
  • Middleburg Heights
  • North Canton
  • Portland
  • Allentown
  • North Charleston
  • Memphis
  • Austin
  • Dallas
  • San Antonio

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.

Who is behind this study?

The study sponsor is Axsome Therapeutics, Inc.

Does this study involve medication?

Yes. The study involves medication, including Solriamfetol and Placebo.

Who can participate?

Listed age limits: 18 years to 56 years.

Is this study still recruiting?

The registry lists this study as enrolling by invitation.

Want to explore more studies?

Explore studies